ID

43687

Beschreibung

Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00367250

Link

https://clinicaltrials.gov/show/NCT00367250

Stichworte

Versionen (2)
  1. 04.05.17 04.05.17 -
  2. 20.09.21 20.09.21 -
Hochgeladen am

20. September 2021

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

  • Neueste
  • Älteste
  • Beliebt
  • Neueste
    • Neueste
    • Älteste
    • Beliebt

Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Metastatic Breast Cancer NCT00367250

Englisch

Eligibility Metastatic Breast Cancer NCT00367250

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of metastatic breast cancer
Beschreibung

Secondary malignant neoplasm of female breast

Datentyp

boolean

Alias
UMLS CUI [1]
C0346993
presence of at least 1 measurable lesion according to modified recist criteria
Beschreibung

Measurable Disease Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
evidence (fluorescence in situ hybridization fish) of
Beschreibung

Evidence Fluorescent in Situ Hybridization

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0332120
UMLS CUI [1,2]
C0162789
her-2 overexpression in tumor tissue:group a: her-2 +++, group b: her-2 + or ++
Beschreibung

HER-2 protein overexpression Tumor tissue | HER2 Positive Score

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1515560
UMLS CUI [1,2]
C0475358
UMLS CUI [2,1]
C3898879
UMLS CUI [2,2]
C0449820
egfr-expressing disease as assessed by immunohistochemistry
Beschreibung

Disease Epidermal Growth Factor Receptor expression | Immunohistochemistry Assessment

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0034802
UMLS CUI [1,3]
C0597360
UMLS CUI [2,1]
C0021044
UMLS CUI [2,2]
C1516048
recovered from relevant toxicities from other treatment prior to study entry
Beschreibung

Toxicity Due to Therapeutic procedure | Patient recovered

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C0087111
UMLS CUI [2]
C1115804
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with trastuzumab for metastatic breast cancer (adjuvant therapy is allowed)
Beschreibung

trastuzumab | Adjuvant therapy Secondary malignant neoplasm of female breast

Datentyp

boolean

Alias
UMLS CUI [1]
C0728747
UMLS CUI [2,1]
C0677850
UMLS CUI [2,2]
C0346993
prior treatment with cetuximab
Beschreibung

cetuximab

Datentyp

boolean

Alias
UMLS CUI [1]
C0995188
concomitant cytotoxic chemotherapy
Beschreibung

Cytotoxic Chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0677881
treatment with any investigational agent(s) within 4 weeks prior to study entry
Beschreibung

Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C0013230
known allergic/hypersensitivity reaction to any of the components of study treatments
Beschreibung

Hypersensitivity Component Investigational Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1705248
UMLS CUI [1,3]
C0949266
severe dyspnea
Beschreibung

Dyspnea Severe

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013404
UMLS CUI [1,2]
C0205082
myocardial infarction within 6 months prior to study entry, uncontrolled congestive heart failure; or any current grade 3 or 4 cardio-vascular disorder despite treatment
Beschreibung

Myocardial Infarction | Congestive heart failure Uncontrolled | Cardiovascular Disease New York Heart Association Classification

Datentyp

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2,1]
C0018802
UMLS CUI [2,2]
C0205318
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0007222
UMLS CUI [3,3]
C1275491
history of significant neurologic or psychiatric disorders
Beschreibung

nervous system disorder | Mental disorders

Datentyp

boolean

Alias
UMLS CUI [1]
C0027765
UMLS CUI [2]
C0004936
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Metastatic Breast Cancer NCT00367250

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Secondary malignant neoplasm of female breast
Item
diagnosis of metastatic breast cancer
boolean
C0346993 (UMLS CUI [1])
Measurable Disease Quantity
Item
presence of at least 1 measurable lesion according to modified recist criteria
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Evidence Fluorescent in Situ Hybridization
Item
evidence (fluorescence in situ hybridization fish) of
boolean
C0332120 (UMLS CUI [1,1])
C0162789 (UMLS CUI [1,2])
HER-2 protein overexpression Tumor tissue | HER2 Positive Score
Item
her-2 overexpression in tumor tissue:group a: her-2 +++, group b: her-2 + or ++
boolean
C1515560 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
C3898879 (UMLS CUI [2,1])
C0449820 (UMLS CUI [2,2])
Disease Epidermal Growth Factor Receptor expression | Immunohistochemistry Assessment
Item
egfr-expressing disease as assessed by immunohistochemistry
boolean
C0012634 (UMLS CUI [1,1])
C0034802 (UMLS CUI [1,2])
C0597360 (UMLS CUI [1,3])
C0021044 (UMLS CUI [2,1])
C1516048 (UMLS CUI [2,2])
Toxicity Due to Therapeutic procedure | Patient recovered
Item
recovered from relevant toxicities from other treatment prior to study entry
boolean
C0600688 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C1115804 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
trastuzumab | Adjuvant therapy Secondary malignant neoplasm of female breast
Item
prior treatment with trastuzumab for metastatic breast cancer (adjuvant therapy is allowed)
boolean
C0728747 (UMLS CUI [1])
C0677850 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
cetuximab
Item
prior treatment with cetuximab
boolean
C0995188 (UMLS CUI [1])
Cytotoxic Chemotherapy
Item
concomitant cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1])
Investigational New Drugs
Item
treatment with any investigational agent(s) within 4 weeks prior to study entry
boolean
C0013230 (UMLS CUI [1])
Hypersensitivity Component Investigational Therapy
Item
known allergic/hypersensitivity reaction to any of the components of study treatments
boolean
C0020517 (UMLS CUI [1,1])
C1705248 (UMLS CUI [1,2])
C0949266 (UMLS CUI [1,3])
Dyspnea Severe
Item
severe dyspnea
boolean
C0013404 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Myocardial Infarction | Congestive heart failure Uncontrolled | Cardiovascular Disease New York Heart Association Classification
Item
myocardial infarction within 6 months prior to study entry, uncontrolled congestive heart failure; or any current grade 3 or 4 cardio-vascular disorder despite treatment
boolean
C0027051 (UMLS CUI [1])
C0018802 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0007222 (UMLS CUI [3,2])
C1275491 (UMLS CUI [3,3])
nervous system disorder | Mental disorders
Item
history of significant neurologic or psychiatric disorders
boolean
C0027765 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video